Technical Roundup on Biotech Stocks -- Keryx Biopharma, Inovio Pharma, Seattle Genetics, and Arrowhead Pharma

Aug 30, 2016, 08:15 ET from Chelmsford Park SA

NEW YORK, August 30, 2016 /PRNewswire/ --

The Biotech arena includes companies that use biological processes to develop technological solutions, and manufacture products intended to improve the quality of life. Stocks under assessment on today are: Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Inovio Pharmaceuticals Inc. (NASDAQ: INO), Seattle Genetics Inc. (NASDAQ: SGEN), and Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR). Sign up today and download for free the research reports for the stocks covered today at:

Keryx Biopharma  

On Monday, shares in Boston, Massachusetts headquartered Keryx Biopharmaceuticals Inc. ended the day 5.47% lower at $4.32. The stock recorded a trading volume of 2.08 million shares, which was above its three months average volume of 1.68 million shares. The Company's shares are trading below their 200-day moving average by 14.62%. Furthermore, shares of Keryx Biopharmaceuticals, which focuses on providing therapies for patients with renal disease in the US, have a Relative Strength Index (RSI) of 33.93.

On August 1st, 2016, Keryx Biopharmaceuticals announced that an interruption in the supply of Auryxia® tablets is imminent due to a production-related issue converting active pharmaceutical ingredient to finished drug product. Keryx expects to make Auryxia available to patients when supply of Auryxia is back to adequate levels, which Keryx anticipates will be during the fourth quarter of 2016.

On August 02nd, 2016, research firm Stifel downgraded the Company's stock rating from 'Buy' to 'Hold'. KERX complete research report is just a click away at:

Inovio Pharma  

Plymouth Meeting, Pennsylvania headquartered Inovio Pharmaceuticals Inc.'s stock finished the session 4.63% higher at $9.27. A total volume of 2.83 million shares was traded, which was above their three months average volume of 1.51 million shares. The Company's shares have surged 37.95% on an YTD basis. The stock is trading above its 200-day moving average by 12.51%. Moreover, shares of Inovio Pharmaceuticals, which develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases, have an RSI of 53.37.

On August 09th, 2016, research firm Maxim Group downgraded the Company's stock rating from 'Buy' to 'Hold'.

On August 29th, 2016, Inovio Pharmaceuticals announced that it has initiated a clinical study of its preventive Zika vaccine (GLS-5700) in 160 subjects in Puerto Rico, where the Zika virus outbreak has been declared a public health emergency. In June, Inovio was the first to commence a human Zika trial, with sites in the U.S. and Canada. All 40 subjects for the first clinical study have been fully enrolled and dosed. Inovio expects to report results before the end of this year. The complimentary report on INO can be downloaded at:

Seattle Genetics  

Shares in Bothell, Washington headquartered Seattle Genetics Inc. ended Monday's session 0.13% higher at $45.36. The stock recorded a trading volume of 437,056 shares. The Company's shares have gained 12.19% over the previous three months and 1.07% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 3.80% and 16.88%, respectively. Moreover, shares of Seattle Genetics, which develops and commercializes targeted therapies for the treatment of cancer worldwide, have an RSI of 49.59.

On August 1st, 2016, Takeda Pharmaceutical Company Limited and Seattle Genetics announced that the Phase 3 ALCANZA clinical trial evaluating ADCETRIS in patients with cutaneous T-cell lymphoma met its primary endpoint, demonstrating a highly statistically significant improvement in the rate of objective response lasting at least four months. This randomized trial, which received a Special Protocol Assessment from the U.S. FDA and scientific advice from the European Medicines Agency, compared the use of single-agent ADCETRIS to a control arm of investigator's choice of standard therapies, methotrexate or bexarotene, in 131 patients with CD30-expressing CTCL who received prior systemic or radiation therapy. Sign up for your complimentary report on SGEN at:

Arrowhead Pharma  

Pasadena, California headquartered Arrowhead Pharmaceuticals Inc.'s shares recorded a trading volume of 767,151 shares, which was higher than their three months average volume of 602,010 shares. The stock closed 0.86% lower at $6.89. The Company's shares have gained 15.60% in the past month, 12.40% over the previous three months, and 12.03% since the start of this year. The stock is trading 15.44% above its 50-day moving average and 28.66% above its 200-day moving average. Additionally, shares of Arrowhead Pharmaceuticals, which develops novel drugs to treat intractable diseases in the US, have an RSI of 56.91.

On August 12th, 2016, Arrowhead Pharmaceuticals announced that it closed a previously announced private offering with a select group of investors. Gross proceeds were $45 million. Approximately 7.63 million shares of common stock were issued at a price of $5.90 per share.

On August 18th, 2016, research firm Cantor Fitzgerald initiated a 'Buy' rating on the Company's stock, issuing a target price of $15 per share. Download the research report for free on ARWR at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number:  +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA